Alle verbonden artikelen

Breast Cancer. Side Effects of Medical Cancer Therapy: Prevention and Treatment. Ed. Mario A. Dicato. Chapter 2: P29-117; Springer 2013, XIII.

Auteurs : Aftimos P, Gombos A, Pugliano L, Awada A, Piccart-Gebhart M
Jaar : 2013
Journal : Book
Volume : chapter2
Pagina's : P29-117

Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.

Auteurs : Campone M, Beck JT, Gnant M, Neven P, Pritchard KI, Bachelot T, Provencher L, Rugo HS, Piccart-Gebhart M, Hortobagyi GN, Nunzi M, Heng DY, Baselga J, Komorowski A, Noguchi S, Horiguchi J, Bennett L, Ziemiecki R, Zhang J, Cahana A, Taran T, Sahmoud T, Burris HA
Jaar : 2013
Journal : Curr Med Res Opin
Volume : 29(11)
Pagina's : 1463-73

Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology.

Auteurs : Borbath I, Ceratti A, Verslype C, Demols A, Delaunoit T, Laurent S, Deleporte A, Vergauwe P, Van Maanen A, Sempoux C, van Cutsem E, Van Laethem JL
Jaar : 2013
Journal : Ann Oncol
Volume : 24(11)
Pagina's : 2824-9

Histiocytose agressive à cellules de Langerhans 20 ans après un cancer du sein : à propos d’un cas.

Auteurs : Zakkouri F, Klastersky J, Alexiou J, de Saint-Aubain de Somerhausen N, Flamen P, Firescu R, Georgala A, Awada A
Jaar : 2013
Journal : J Am Soc Echocardiogr
Volume : 5
Pagina's : 220-223

Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.

Auteurs : Pritchard KI, Burris HA, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN, Campone M, Csöszi T, Baselga J, Puttawibul P, Piccart-Gebhart M, Heng D, Noguchi S, Srimuninnimit V, Bourgeois H, Gonzalez Martin A, Osborne K, Panneerselvam A, Taran T, Sahmoud T, Gnant M
Jaar : 2013
Journal : Clin Breast Cancer
Volume : 13(6)
Pagina's : 421-432.e8

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.

Auteurs : Goldhirsch A, Winer EP, Coates AS, Gelber Rd, Piccart-Gebhart M, Thürlimann B, Senn HJ
Jaar : 2013
Journal : Ann Oncol
Volume : 24(9)
Pagina's : 2206-23

Pertuzumab: new hope for patients with HER2-positive breast cancer.

Auteurs : Capelan M, Pugliano L, de Azambuja E, Bozovic I, Saini KS, Sotiriou C, Loi S, Piccart-Gebhart M
Jaar : 2013
Journal : Ann Oncol
Volume : 24(2)
Pagina's : 273-82

Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial.

Auteurs : Partridge AH, Gelber S, Piccart-Gebhart M, Focant F, Scullion M, Holmes E, Winer EP, Gelber Rd
Jaar : 2013
Journal : J. Clin. Oncol.
Volume : 31(21)
Pagina's : 2692-8

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.

Auteurs : Martin M, Bonneterre J, Geyer CE, Ito Y, Ro J, Lang I, Kim SB, Germa C, Vermette J, Wang K, Awada A
Jaar : 2013
Journal : Eur. J. Cancer
Volume : 49(18)
Pagina's : 3763-72

Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.

Auteurs : Awada A, Dirix L, Manso Sanchez L, Xu B, Luu T, Diéras V, Hershman DL, Agrapart V, Ananthakrishnan R, Staroslawska E
Jaar : 2013
Journal : Ann Oncol
Volume : 24(1)
Pagina's : 109-16

Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer.

Auteurs : Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Piccart-Gebhart M, Joensuu H, Sotiriou C
Jaar : 2013
Journal : J. Natl. Cancer Inst.
Volume : 105(13)
Pagina's : 960-967

Luminal breast cancer: from biology to treatment.

Auteurs : Ignatiadis M, Sotiriou C
Jaar : 2013
Journal : Nat Rev Clin Oncol
Volume : 10(9)
Pagina's : 494-506

Topoisomerase Inhibitors in Metastatic Breast Cancer: Overview of Current Practice and Future Development

Auteurs : Vanderbeeken MC, Aftimos P, Awada A
Jaar : 2013
Journal : Current Breast Cancer Rep
Volume : 5
Pagina's : 31-41

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

Auteurs : Goldhirsch A, Gelber Rd, Piccart-Gebhart M, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, Mcfadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J
Jaar : 2013
Journal : Lancet
Volume : 382(9897)
Pagina's : 1021-8

Impressive response to eribulin in endocrine- and chemotherapy resistant metastatic breast cancer

Auteurs : Vanderbeeken MC, de Azambuja E
Jaar : 2013
Journal : Belgian J Medical Oncology
Volume : 7(1)
Pagina's : 27-30

Why your preferred targeted drugs may become unaffordable.

Auteurs : Piccart-Gebhart M
Jaar : 2013
Journal : Cancer Res
Volume : 73(19)
Pagina's : 5849-51

CD4+ follicular helper T cell infiltration predicts breast cancer survival.

Auteurs : Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, Veys I, Haibe-Kains B, Singhal SK, Michiels S, Rothé F, Salgado R, Duvillier H, Ignatiadis M, Desmedt C, Bron D, Larsimont D, Piccart-Gebhart M, Sotiriou C, Willard-Gallo K
Jaar : 2013
Journal : J Clin Invest
Volume : 123(7)
Pagina's : 2873-92

Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer.

Auteurs : Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pêgo A, Chan A, Goeminne JC, Graas MP, Kennedy MJ, Ciruelos Gil EM, Schneeweiss A, Zubel A, Groos J, Melezínková H, Awada A
Jaar : 2013
Journal : J. Clin. Oncol.
Volume : 31(20)
Pagina's : 2586-92

PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.

Auteurs : Loi S, Michiels S, Baselga J, Bartlett JM, Singhal SK, Sabine VS, Sims AH, Sahmoud T, Dixon JM, Piccart-Gebhart M, Sotiriou C
Jaar : 2013
Journal : PLoS One
Volume : 8(1)
Pagina's : e53292

Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: A rationale to combine targeted drugs based on protein expression inhibition profiles.

Auteurs : Aftimos P, Wiedig M, Langouo Fontsa M, Awada A, Ghanem G, Journe F
Jaar : 2013
Journal : Int J Oncol
Volume : 43(3)
Pagina's : 919-26